- The FDA IND approval marks a pivotal step for the company’s lead compound, known as Lucid-MS.
- What sets Quantum BioPharma’s proprietary treatment apart from most existing MS therapies is its mechanism.
- Lucid-MS previously completed phase 1 clinical trials, showing a favorable safety profile and being well tolerated.
A green light from the U.S. Food and Drug Administration (“FDA”) can turn years of laboratory work into a real shot at treating patients, and that is exactly what just happened for one biopharmaceutical company. Quantum BioPharma (NASDAQ: QNTM), a company focused on neurodegenerative and metabolic disorders, announced that the FDA has approved its Investigational New Drug (“IND”) application for Lucid-MS, clearing the path to phase 2 clinical testing of its multiple sclerosis (“MS”) candidate.
The announcement marks a pivotal step for the company’s lead compound, known as Lucid-MS. With the IND now approved, Quantum BioPharma can begin recruiting patients and administering the drug in a controlled clinical setting, something that was not possible without FDA clearance.
According to the announcement, the upcoming study will be randomized, double blind and placebo controlled, a design considered the gold standard for testing whether a new drug actually works. Researchers plan to measure efficacy, safety and tolerability in people living with MS, tracking both clinical symptoms and radiological changes in the brain. Site selection and other trial start-up activities are already underway, with patient enrollment expected to begin as soon as possible.
What sets Lucid-MS apart from most existing MS therapies is its mechanism. The compound is designed to protect nerve cells by inhibiting demyelination, the breakdown of the fatty sheath that insulates nerve fibers. This sheath is critical in allowing the brain to communicate effectively with the rest of the body. Most currently approved MS drugs instead work by suppressing or modulating the immune system, an approach that can leave patients vulnerable to infections and other side effects.
Lucid-MS targets an enzyme called peptidyl arginine deiminase 2, or PAD2, which has been implicated in the breakdown of myelin when its activity is increased. In preclinical models, the compound demonstrated the ability to protect the myelin sheath from this type of damage, supporting its potential as a neuroprotective approach in MS. The company notes that the compound also was not found to suppress the immune system, distinguishing its proposed approach from most currently marketed treatments.
Before reaching this milestone, Lucid-MS completed phase 1 clinical trials in healthy human volunteers. Quantum BioPharma reported that the drug showed a favorable safety profile and was well tolerated in that earlier testing, an important precondition for moving into a patient population. The underlying science behind the compound has also been published in peer-reviewed journals, including the Journal of Medicinal Chemistry and the Proceedings of the National Academy of Sciences.
Quantum BioPharma also disclosed its financial position alongside the clinical update. The company reported approximately $10 million in cash, digital assets and liquid investments as of June 30, 2026, providing some runway as it moves into the more resource-intensive phase 2 stage of development.
There is no cure for multiple sclerosis today, and the disease remains a leading cause of neurological disability among young adults. The FDA’s clearance does not guarantee that Lucid-MS will ultimately prove effective or reach the market; all drug candidates that begin clinical trials do not receive final approval. Phase 2 testing exists specifically to answer the question of a drug’s effectiveness and safety, gathering real-world data on how the drug performs against a placebo in an actual patient population.
However, for a company still in the clinical stage of development, an FDA clearance represents significant forward momentum. Investors and patients alike will likely be watching for updates on site activation, enrollment progress and eventual trial data as Quantum BioPharma works to advance a treatment approach it believes is fundamentally different from what is currently available.
For more information, visit www.QuantumBioPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to QNTM are available in the company’s newsroom at https://nnw.fm/QNTM
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
Austin, Texas
www.NetworkNewsWire.com
512.354.7000 Office
[email protected]
NetworkNewsWire is powered by IBN
